FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025973346> ?p ?o ?g. }

• W3025973346 endingPage "1430" @default.
• W3025973346 startingPage "1420" @default.
• W3025973346 abstract "Background Hypogammaglobulinemia (serum IgG levels < 7.0 g/L) has been associated with increased risk of COPD exacerbations but has not yet been shown to predict hospitalizations. Research Question To determine the relationship between hypogammaglobulinemia and the risk of hospitalization in patients with COPD. Study Design and Methods Serum IgG levels were measured on baseline samples from four COPD cohorts (n = 2,259): Azithromycin for Prevention of AECOPD (MACRO, n = 976); Simvastatin in the Prevention of AECOPD (STATCOPE, n = 653), Long-Term Oxygen Treatment Trial (LOTT, n = 354), and COPD Activity: Serotonin Transporter, Cytokines and Depression (CASCADE, n = 276). IgG levels were determined by immunonephelometry (MACRO; STATCOPE) or mass spectrometry (LOTT; CASCADE). The effect of hypogammaglobulinemia on COPD hospitalization risk was evaluated using cumulative incidence functions for this outcome and deaths (competing risk). Fine-Gray models were performed to obtain adjusted subdistribution hazard ratios (SHR) related to IgG levels for each study and then combined using a meta-analysis. Rates of COPD hospitalizations per person-year were compared according to IgG status. Results The overall frequency of hypogammaglobulinemia was 28.4%. Higher incidence estimates of COPD hospitalizations were observed among participants with low IgG levels compared with those with normal levels (Gray’s test, P < .001); pooled SHR (meta-analysis) was 1.29 (95% CI, 1.06-1.56, P = .01). Among patients with prior COPD admissions (n = 757), the pooled SHR increased to 1.58 (95% CI, 1.20-2.07, P < .01). The risk of COPD admissions, however, was similar between IgG groups in patients with no prior hospitalizations: pooled SHR = 1.15 (95% CI, 0.86-1.52, P =.34). The hypogammaglobulinemia group also showed significantly higher rates of COPD hospitalizations per person-year: 0.48 ± 2.01 vs 0.29 ± 0.83, P < .001. Interpretation Hypogammaglobulinemia is associated with a higher risk of COPD hospital admissions. Hypogammaglobulinemia (serum IgG levels < 7.0 g/L) has been associated with increased risk of COPD exacerbations but has not yet been shown to predict hospitalizations. To determine the relationship between hypogammaglobulinemia and the risk of hospitalization in patients with COPD. Serum IgG levels were measured on baseline samples from four COPD cohorts (n = 2,259): Azithromycin for Prevention of AECOPD (MACRO, n = 976); Simvastatin in the Prevention of AECOPD (STATCOPE, n = 653), Long-Term Oxygen Treatment Trial (LOTT, n = 354), and COPD Activity: Serotonin Transporter, Cytokines and Depression (CASCADE, n = 276). IgG levels were determined by immunonephelometry (MACRO; STATCOPE) or mass spectrometry (LOTT; CASCADE). The effect of hypogammaglobulinemia on COPD hospitalization risk was evaluated using cumulative incidence functions for this outcome and deaths (competing risk). Fine-Gray models were performed to obtain adjusted subdistribution hazard ratios (SHR) related to IgG levels for each study and then combined using a meta-analysis. Rates of COPD hospitalizations per person-year were compared according to IgG status. The overall frequency of hypogammaglobulinemia was 28.4%. Higher incidence estimates of COPD hospitalizations were observed among participants with low IgG levels compared with those with normal levels (Gray’s test, P < .001); pooled SHR (meta-analysis) was 1.29 (95% CI, 1.06-1.56, P = .01). Among patients with prior COPD admissions (n = 757), the pooled SHR increased to 1.58 (95% CI, 1.20-2.07, P < .01). The risk of COPD admissions, however, was similar between IgG groups in patients with no prior hospitalizations: pooled SHR = 1.15 (95% CI, 0.86-1.52, P =.34). The hypogammaglobulinemia group also showed significantly higher rates of COPD hospitalizations per person-year: 0.48 ± 2.01 vs 0.29 ± 0.83, P < .001. Hypogammaglobulinemia is associated with a higher risk of COPD hospital admissions. Hypogammaglobulinemia in COPD: Treatable Phenotype or Surrogate Marker?CHESTVol. 158Issue 4PreviewWith the recognition of COPD as a heterogeneous disease, clinical phenotyping has allowed for grouping of individuals based on clinically relevant characteristics. Thus far, categorization of patients with COPD into a variety of phenotypes has resulted in a limited number of individualized treatment strategies, which has heightened the emphasis on achieving personalized therapeutics.1 In parallel, a variety of serologic markers thought to be of clinical relevance in COPD have been investigated. Despite identification of several biomarkers associated with COPD outcomes and disease progression, results have been inconsistent and the identified biomarkers are not clearly augmentable. Full-Text PDF" @default.
• W3025973346 created "2020-05-21" @default.
• W3025973346 creator A5001041746 @default.
• W3025973346 creator A5003851805 @default.
• W3025973346 creator A5004080024 @default.
• W3025973346 creator A5009003396 @default.
• W3025973346 creator A5014654052 @default.
• W3025973346 creator A5021720934 @default.
• W3025973346 creator A5021843102 @default.
• W3025973346 creator A5026096786 @default.
• W3025973346 creator A5028571055 @default.
• W3025973346 creator A5028580215 @default.
• W3025973346 creator A5030333301 @default.
• W3025973346 creator A5032434310 @default.
• W3025973346 creator A5037106670 @default.
• W3025973346 creator A5042031961 @default.
• W3025973346 creator A5042188739 @default.
• W3025973346 creator A5045850263 @default.
• W3025973346 creator A5046559339 @default.
• W3025973346 creator A5052489787 @default.
• W3025973346 creator A5058532986 @default.
• W3025973346 creator A5060850749 @default.
• W3025973346 creator A5067072009 @default.
• W3025973346 creator A5067641826 @default.
• W3025973346 creator A5067787766 @default.
• W3025973346 creator A5068113021 @default.
• W3025973346 creator A5068244386 @default.
• W3025973346 creator A5071121607 @default.
• W3025973346 creator A5079066516 @default.
• W3025973346 creator A5082568705 @default.
• W3025973346 creator A5083798425 @default.
• W3025973346 creator A5086183479 @default.
• W3025973346 creator A5089798726 @default.
• W3025973346 date "2020-10-01" @default.
• W3025973346 modified "2023-10-18" @default.
• W3025973346 title "Serum IgG Levels and Risk of COPD Hospitalization" @default.
• W3025973346 cites W1889295436 @default.
• W3025973346 cites W1892457185 @default.
• W3025973346 cites W1952002227 @default.
• W3025973346 cites W1963778872 @default.
• W3025973346 cites W2013827316 @default.
• W3025973346 cites W2022410416 @default.
• W3025973346 cites W2040944404 @default.
• W3025973346 cites W2070935883 @default.
• W3025973346 cites W2073140442 @default.
• W3025973346 cites W2088095316 @default.
• W3025973346 cites W2096373158 @default.
• W3025973346 cites W2100698941 @default.
• W3025973346 cites W2100858113 @default.
• W3025973346 cites W2103225875 @default.
• W3025973346 cites W2112089291 @default.
• W3025973346 cites W2112162293 @default.
• W3025973346 cites W2112792240 @default.
• W3025973346 cites W2117426933 @default.
• W3025973346 cites W2117837864 @default.
• W3025973346 cites W2118939220 @default.
• W3025973346 cites W2122790962 @default.
• W3025973346 cites W2125435699 @default.
• W3025973346 cites W2139223643 @default.
• W3025973346 cites W2147438174 @default.
• W3025973346 cites W2152924515 @default.
• W3025973346 cites W2156617860 @default.
• W3025973346 cites W2164581678 @default.
• W3025973346 cites W2167022863 @default.
• W3025973346 cites W2169656611 @default.
• W3025973346 cites W2254159112 @default.
• W3025973346 cites W2264767503 @default.
• W3025973346 cites W2317300697 @default.
• W3025973346 cites W2531618711 @default.
• W3025973346 cites W2557938954 @default.
• W3025973346 cites W2566579337 @default.
• W3025973346 cites W2587928371 @default.
• W3025973346 cites W2605067265 @default.
• W3025973346 cites W2608657747 @default.
• W3025973346 cites W2746473595 @default.
• W3025973346 cites W2754160328 @default.
• W3025973346 cites W2765513486 @default.
• W3025973346 cites W2765551854 @default.
• W3025973346 cites W2782597408 @default.
• W3025973346 cites W2788260294 @default.
• W3025973346 cites W2798173619 @default.
• W3025973346 cites W2895869275 @default.
• W3025973346 cites W2920797638 @default.
• W3025973346 cites W4210988223 @default.
• W3025973346 doi "https://doi.org/10.1016/j.chest.2020.04.058" @default.
• W3025973346 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32439504" @default.
• W3025973346 hasPublicationYear "2020" @default.
• W3025973346 type Work @default.
• W3025973346 sameAs 3025973346 @default.
• W3025973346 citedByCount "18" @default.
• W3025973346 countsByYear W30259733462020 @default.
• W3025973346 countsByYear W30259733462021 @default.
• W3025973346 countsByYear W30259733462022 @default.
• W3025973346 countsByYear W30259733462023 @default.
• W3025973346 crossrefType "journal-article" @default.
• W3025973346 hasAuthorship W3025973346A5001041746 @default.
• W3025973346 hasAuthorship W3025973346A5003851805 @default.
• W3025973346 hasAuthorship W3025973346A5004080024 @default.

• next